title: Late seroconversion and high chronicity rate of hepatitis C virus infection in patients with hematologic disorders.
abstract: BACKGROUND
  Patients with hematologic disorders requiring repeated blood and platelet transfusions are at high risk for development of post-transfusion non-A, non-B hepatitis.
  
  
  METHODS
  Fifty-five patients with hematologic diseases and post-transfusion non-A, non-B hepatitis were studied. Sera were assayed for hepatitis C virus (HCV) antibodies with a second-generation enzyme-linked immunoassay. Sera from 40 patients were examined for the presence of HCV RNA with a nested PCR method.
  
  
  RESULTS
  The clinical picture of acute non-A, non-B hepatitis did not differ from that described in other patient groups: however, progression to chronic hepatitis was very common (95%). Thirty-eight (95%) of 40 patients, whose sera were analysed both serologically and for the presence of HCV RNA had verified HCV infections. In some patients time to seroconversion was prolonged, up to more than 14 months. Seventeen patients with resistant or relapsed acute leukemia were treated with combination chemotherapy during the acute or chronic phase of hepatitis. Suppression of the inflammatory activity as reflected by a decrease of serum aminotransferase levels was recorded during the subsequent pancytopenic period.
  
  
  CONCLUSIONS
  Hepatitis C has a high chronicity rate in patients with hematologic disorders which parallels the situation of hepatitis B in the immunocompromised host. Furthermore, like the situation in hepatitis B, the hosts' immune response to infection seems to be involved in the pathogenesis of liver injury. Time to seroconversion may be prolonged and detection of HCV RNA is therefore important for diagnosis.
authors.affiliation: Division of Medicine, Karolinska Hospital, Stockholm, Sweden.
authors.forename: A
authors.initials: A
authors.lastname: Gruber
authors.forename: H
authors.initials: H
authors.lastname: Norder
authors.forename: L
authors.initials: L
authors.lastname: Magnius
authors.forename: M
authors.initials: M
authors.lastname: Rotzén
authors.forename: C
authors.initials: C
authors.lastname: Rubio
authors.forename: L
authors.initials: L
authors.lastname: Grillner
authors.forename: M
authors.initials: M
authors.lastname: Björkholm
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000917:Antibody Formation; D002908:Chronic Disease; D005260:Female; D006402:Hematologic Diseases / Q000150:complications / Q000628:therapy*; D016174:Hepacivirus / Q000276:immunology / Q000302:isolation & purification; D006508:Hepatitis Antibodies / Q000097:blood; D006526:Hepatitis C / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D018937:Hepatitis C Antibodies; D006801:Humans; D007938:Leukemia / Q000150:complications / Q000188:drug therapy; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D013997:Time Factors; D065227:Transfusion Reaction
chemical_list: D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies; D012367:RNA, Viral